Key Points
- EVP Scott Dreyer sold 17,600 shares of Collegium on Dec. 8 at an average price of $48.17 for proceeds of $847,792, reducing his stake by 14.52% to 103,613 shares; the transaction is disclosed in an SEC Form 4 filing.
- Collegium (NASDAQ:COLL) trades near $48.86 with a market cap of about $1.54 billion, a P/E of ~30.35, a 12‑month range of $23.23–$49.09, and 50-/200‑day moving averages of ~$40.14/$35.71.
- Analyst sentiment is broadly positive—one Strong Buy, five Buys and one Hold—with an average price target of $47 and recent upgrades including Barclays' $58 target and other firms raising ratings.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Scott Dreyer sold 17,600 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares of the company's stock, valued at $4,991,038.21. This trade represents a 14.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Collegium Pharmaceutical Price Performance
Shares of NASDAQ:COLL opened at $48.86 on Thursday. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of 30.35 and a beta of 0.61. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $49.09. The stock's 50 day moving average price is $40.14 and its 200 day moving average price is $35.71.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $135.55 million during the quarter. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Collegium Pharmaceutical
Large investors have recently made changes to their positions in the company. Illinois Municipal Retirement Fund lifted its holdings in shares of Collegium Pharmaceutical by 1.6% during the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company's stock worth $605,000 after buying an additional 278 shares during the last quarter. Vident Advisory LLC raised its stake in Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company's stock valued at $541,000 after purchasing an additional 281 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company's stock valued at $31,000 after purchasing an additional 350 shares during the period. Assetmark Inc. grew its position in Collegium Pharmaceutical by 8.4% in the 3rd quarter. Assetmark Inc. now owns 4,551 shares of the specialty pharmaceutical company's stock worth $159,000 after purchasing an additional 352 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Collegium Pharmaceutical by 1.4% during the 2nd quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company's stock worth $863,000 after purchasing an additional 409 shares during the period.
Analysts Set New Price Targets
A number of research analysts recently issued reports on COLL shares. Wall Street Zen raised Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Zacks Research raised shares of Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 21st. Barclays initiated coverage on shares of Collegium Pharmaceutical in a report on Monday. They issued an "overweight" rating and a $58.00 target price on the stock. Needham & Company LLC restated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Finally, Weiss Ratings upgraded shares of Collegium Pharmaceutical from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of "Buy" and an average price target of $47.00.
View Our Latest Analysis on COLL
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
